INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 203 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,858 | -12.9% | 61,331 | 0.0% | 0.00% | – |
| Q2 2023 | $27,384 | -51.7% | 61,331 | -11.3% | 0.00% | – |
| Q1 2023 | $56,697 | -39.1% | 69,143 | +15.8% | 0.00% | – |
| Q4 2022 | $93,161 | +9.6% | 59,719 | +20.6% | 0.00% | – |
| Q3 2022 | $85,000 | +39.3% | 49,531 | +41.4% | 0.00% | – |
| Q2 2022 | $61,000 | -57.9% | 35,036 | -13.3% | 0.00% | – |
| Q1 2022 | $145,000 | -32.9% | 40,395 | -6.5% | 0.00% | – |
| Q4 2021 | $216,000 | -48.4% | 43,194 | -26.2% | 0.00% | – |
| Q3 2021 | $419,000 | -36.8% | 58,526 | -18.2% | 0.00% | – |
| Q2 2021 | $663,000 | -6.9% | 71,587 | -6.7% | 0.00% | -100.0% |
| Q1 2021 | $712,000 | +7.2% | 76,723 | +2.3% | 0.00% | – |
| Q4 2020 | $664,000 | +28.9% | 75,029 | +68.7% | 0.00% | – |
| Q3 2020 | $515,000 | -58.1% | 44,470 | -2.4% | 0.00% | -100.0% |
| Q2 2020 | $1,228,000 | +1279.8% | 45,576 | +281.6% | 0.00% | – |
| Q1 2020 | $89,000 | +107.0% | 11,944 | -9.1% | 0.00% | – |
| Q4 2019 | $43,000 | -27.1% | 13,136 | -54.4% | 0.00% | – |
| Q3 2019 | $59,000 | -23.4% | 28,783 | +10.1% | 0.00% | – |
| Q2 2019 | $77,000 | -16.3% | 26,131 | +6.7% | 0.00% | – |
| Q1 2019 | $92,000 | -5.2% | 24,494 | +1.4% | 0.00% | – |
| Q4 2018 | $97,000 | -40.1% | 24,154 | -17.3% | 0.00% | – |
| Q3 2018 | $162,000 | +62.0% | 29,216 | +14.0% | 0.00% | – |
| Q2 2018 | $100,000 | -21.3% | 25,630 | -5.4% | 0.00% | – |
| Q1 2018 | $127,000 | +11.4% | 27,085 | -1.6% | 0.00% | – |
| Q4 2017 | $114,000 | +72.7% | 27,515 | +163.2% | 0.00% | – |
| Q3 2017 | $66,000 | -32.0% | 10,454 | -15.7% | 0.00% | – |
| Q2 2017 | $97,000 | -67.7% | 12,405 | -72.6% | 0.00% | – |
| Q1 2017 | $300,000 | -4.2% | 45,203 | 0.0% | 0.00% | – |
| Q4 2016 | $313,000 | +182.0% | 45,203 | +280.3% | 0.00% | – |
| Q3 2016 | $111,000 | +2.8% | 11,885 | +1.8% | 0.00% | – |
| Q2 2016 | $108,000 | -0.9% | 11,677 | -6.9% | 0.00% | – |
| Q1 2016 | $109,000 | +32.9% | 12,537 | +3.0% | 0.00% | – |
| Q4 2015 | $82,000 | +17.1% | 12,174 | 0.0% | 0.00% | – |
| Q3 2015 | $70,000 | -56.2% | 12,174 | -38.0% | 0.00% | – |
| Q2 2015 | $160,000 | +27.0% | 19,622 | +27.4% | 0.00% | – |
| Q1 2015 | $126,000 | -11.9% | 15,400 | -1.2% | 0.00% | – |
| Q4 2014 | $143,000 | -24.3% | 15,585 | -11.0% | 0.00% | – |
| Q2 2014 | $189,000 | – | 17,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |